NEW YORK (GenomeWeb News) – Peter Schultz has departed as director of the Genomic Institute of the Novartis Research Foundation in San Diego, a position he has held since he founded the institute in 1999.
Schultz disclosed the departure in a revision to his biography on the website of The Scripps Research Institute, where he holds a faculty position as Scripps Family Chair Professor of Chemistry and heads a laboratory focused on the synthesis of molecules and molecular assemblies with novel physical, chemical, or biological properties and functions. The revision to his biography was first reported publicly earlier today by Xconomy San Diego.
Neither Schultz nor a Novartis spokesperson responded to e-mail and telephone messages seeking additional information.
"Given nature's "synthetic" prowess, we have undertaken a biologically inspired approach to synthesis in which the molecules and processes of living organisms are combined with the principles and tools of chemistry to create molecules with new functions difficult to generate by either approach alone," according to an overview of the research included in the website of Schultz's lab at Scripps. "By studying the properties of the resulting molecules, new insights are gained into the molecular mechanisms of complex biological and chemical systems."
According to his bio, Schultz is a founder of Affymax Research Institute, Syrrx, Kalypsys, Phenomix, Symyx Therapeutics, Ilypsa, Ambrx and Wildcat Technologies, eight life sciences companies that according to Schultz were pioneers in the application of diversity based approaches to problems in chemistry, materials science and medicine.